CNIPA.AI

Company patentsCompare

HEAD TO HEAD

AstraZenecaHengrui Pharma

Technology portfolios compared in the same window and counting units. Scale is compared only within the same field or subclass.

Same window · published 2025-01-01 — 2025-12-31Some name or date coverage is incomplete; affected counts are lower bounds

This is a structural comparison of collected portfolios. The same requested window does not establish equal entity scope, covered months or industry; no competitive ranking is inferred.

Applicant-name coverage differs. The counts below cover only the listed names and do not represent complete company portfolios.

AstraZeneca: Applicant names included in these statistics — ASTRAZENECA AB · ASTRAZENECA UK LTDReviewed names not covered — ASTRAZENECA UK LIMITED

Hengrui Pharma: Applicant names included in these statistics — JIANGSU HENGRUI MEDICINE CO · JIANGSU HENGRUI MEDICINE CO LTD · JIANGSU HENGRUI PHARMACEUTICALS CO LTDReviewed names not covered — JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. · 江苏恒瑞医药股份有限公司

Publications
957
Invention share
42%
Concentration
1.00
Green technology
—
Publications
618
Invention share
66%
Concentration
1.23
Green technology
—
0.99Field similarity
Cosine similarity of application counts across 35 fields. 1 is identical, 0 is no overlap.

01Technology field mirror

The 12 fields with the largest combined share. Share shows structure; count shows scale.

Technology field mirror
AstraZenecaTechnology fieldHengrui Pharma
89.6%
Pharmaceuticals
93%
34.3%
Organic fine chemistry
49.7%
26.7%
Biotechnology
34.3%
5.7%
Medical technology
0%
3.1%
Analysis of biological materials
2%
1%
Chemical engineering
0.3%
1.2%
Handling
0%
0.7%
Measurement
0.5%
0%
Macromolecular chemistry, polymers
0.3%
0.3%
Computer technology
0%
0.2%
Control
0%
0.1%
Electrical machinery, apparatus, energy
0%

Inspect one technology field

Inspect collected applications, portfolio share and supporting publications within one field. A technology overlap does not establish that companies in different industries are direct competitors.

One application may belong to multiple fields, so shares can sum to more than 100%. Drill-down lists publications; an application publication and its grant may appear separately.

02Same problem: shared IPC subclasses

The 10 subclasses in every company's top 60 with the most combined applications. Scale is compared within a subclass, never across different business scopes.

A61K
AstraZeneca770
Hengrui Pharma539
A61P
AstraZeneca716
Hengrui Pharma504
C07DHeterocyclic compounds
AstraZeneca288
Hengrui Pharma270
C07K
AstraZeneca197
Hengrui Pharma196
C12NMicroorganisms, enzymes
AstraZeneca70
Hengrui Pharma70
C07C
AstraZeneca14
Hengrui Pharma45
G01NAnalysing materials
AstraZeneca28
Hengrui Pharma14
C07F
AstraZeneca17
Hengrui Pharma10
C07H
AstraZeneca9
Hengrui Pharma12
C12QBiochemical testing
AstraZeneca5
Hengrui Pharma5

03Where each one leans

Observed emphasis within each company’s collected top-60 IPC subclasses. A dash for another company means outside its top-60 list, not zero applications or a market gap. Incomplete coverage can also change the ordering.

AstraZeneca

  • A61M
    AstraZeneca
    18
    Hengrui Pharma
    —
  • A61J
    AstraZeneca
    11
    Hengrui Pharma
    —
  • B65DContainers, packaging
    AstraZeneca
    11
    Hengrui Pharma
    —
  • B01DSeparation, filtering
    AstraZeneca
    8
    Hengrui Pharma
    —
  • G16H
    AstraZeneca
    7
    Hengrui Pharma
    —
  • G01NAnalysing materials
    AstraZeneca
    28
    Hengrui Pharma
    14

Hengrui Pharma

  • C07DHeterocyclic compounds
    AstraZeneca
    288
    Hengrui Pharma
    270
  • C07K
    AstraZeneca
    197
    Hengrui Pharma
    196
  • A61K
    AstraZeneca
    770
    Hengrui Pharma
    539
  • A61P
    AstraZeneca
    716
    Hengrui Pharma
    504
  • C07C
    AstraZeneca
    14
    Hengrui Pharma
    45
  • C12NMicroorganisms, enzymes
    AstraZeneca
    70
    Hengrui Pharma
    70

04Publication rhythm

AstraZenecaHengrui PharmaPublications per period
Publications per period
PeriodAstraZenecaHengrui Pharma
2025-01≥79 (partial coverage)≥33 (partial coverage)
2025-02≥83 (partial coverage)≥41 (partial coverage)
2025-03≥111 (partial coverage)≥82 (partial coverage)
2025-04≥93 (partial coverage)≥52 (partial coverage)
2025-05≥70 (partial coverage)≥61 (partial coverage)
2025-06≥72 (partial coverage)≥50 (partial coverage)
2025-07≥73 (partial coverage)≥57 (partial coverage)
2025-08≥74 (partial coverage)≥44 (partial coverage)
2025-09≥70 (partial coverage)≥51 (partial coverage)
2025-10≥70 (partial coverage)≥47 (partial coverage)
2025-11≥68 (partial coverage)≥50 (partial coverage)
2025-12≥94 (partial coverage)≥50 (partial coverage)

Empty dashed outlines mark uncollected periods. Hatched bars and ≥ counts mark partial coverage.

Publication timing follows examination and publication cycles, not R&D intensity.

What makes it comparableThe same publication window and counting units. Companies with different windows are not put in one comparison.

What is not comparableGroup totals. Business and entity scopes differ; compare scale within a field or subclass.

Not a rankingSimilarity and shares describe structure, not patent value, quality or technical leadership.